OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+29.48%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$215M
AUM Growth
+$215M
(+8.8%)
Cap. Flow
-$17.2M
Cap. Flow
% of AUM
-8.01%
Top 10 Holdings %
Top 10 Hldgs %
52.76%
Holding
47
New
11
Increased
10
Reduced
9
Closed
10
Top Buys
| 1 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$10.4M |
| 2 |
MiMedx Group
MDXG
|
$6.14M |
| 3 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$4.46M |
| 4 |
AMRN
Amarin Corp
AMRN
|
$4.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$3.97M |
Top Sells
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
$10.4M |
| 2 |
Travere Therapeutics
TVTX
|
$10.1M |
| 3 |
CMRX
Chimerix, Inc.
CMRX
|
$9.05M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
$5.28M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$4.56M |
Sector Composition
| 1 | Healthcare | 83.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
| $21.3M | 9.89% | 565,000 -240,000 | -30% | -$9.05M |
|
|
CEMP
2
DELISTED
Cempra, Inc.
CEMP
| $17.2M | 7.96% | 500,000 -4,800 | -1% | -$165K |
|
|
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $12.4M | 5.74% | 1,500,000 -25,000 | -2% | -$206K |
|
|
4
Travere Therapeutics
TVTX
$1.56B
| $12M | 5.56% | 500,000 -420,000 | -46% | -$10.1M |
|
|
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.4M | 4.82% | 140,000 | – | – |
|
|
AMAG
6
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $10.4M | 4.82% | +190,000 | New | +$10.4M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $8.49M | 3.94% | 90,000 -23,500 | -21% | -$2.22M |
|
8
Codexis
CDXS
$246M
| $7.86M | 3.65% | 1,724,000 | – | – |
|
9
Geron
GERN
$893M
| $6.88M | 3.19% | 1,825,000 | – | – |
|
|
GNMX
10
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $6.85M | 3.18% | 850,000 | – | – |
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $6.83M | 3.17% | 110,000 +3,800 | +4% | +$236K |
|
12
Supernus Pharmaceuticals
SUPN
$2.53B
| $6.47M | 3% | 535,000 +185,000 | +53% | +$2.24M |
|
|
TTPH
13
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $6.41M | 2.98% | 175,000 -14,700 | -8% | -$539K |
|
|
INSY
14
DELISTED
Insys Therapeutics, Inc.
INSY
| $6.39M | 2.97% | 110,000 -12,500 | -10% | -$727K |
|
|
15
MiMedx Group
MDXG
$1.05B
| $6.14M | 2.85% | +590,000 | New | +$6.14M |
|
16
FibroGen
FGEN
$47.8M
| $6M | 2.79% | 191,338 | – | – |
|
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $5.76M | 2.67% | 145,000 +100,000 | +222% | +$3.97M |
|
18
Harrow
HROW
$1.44B
| $5.49M | 2.55% | 687,100 +127,100 | +23% | +$1.02M |
|
|
AVDL
19
Avadel Pharmaceuticals
AVDL
$1.43B
| $5.39M | 2.5% | 300,000 +95,000 | +46% | +$1.71M |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.26M | 2.44% | 260,000 -73,333 | -22% | -$1.48M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.89M | 2.27% | 105,000 +5,000 | +5% | +$233K |
|
|
ADMS
22
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $4.46M | 2.07% | +255,000 | New | +$4.46M |
|
|
KITE
23
DELISTED
Kite Pharma, Inc.
KITE
| $4.38M | 2.04% | 76,000 | – | – |
|
|
AMRN
24
Amarin Corp
AMRN
$311M
| $4.1M | 1.91% | +1,754,000 | New | +$4.1M |
|
25
Axogen
AXGN
$743M
| $3.45M | 1.6% | +985,900 | New | +$3.45M |
|